Lynda Grinsted

2.6k total citations · 2 hit papers
19 papers, 1.4k citations indexed

About

Lynda Grinsted is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Lynda Grinsted has authored 19 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 10 papers in Molecular Biology. Recurrent topics in Lynda Grinsted's work include PI3K/AKT/mTOR signaling in cancer (8 papers), Advanced Breast Cancer Therapies (6 papers) and Cancer Treatment and Pharmacology (5 papers). Lynda Grinsted is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (8 papers), Advanced Breast Cancer Therapies (6 papers) and Cancer Treatment and Pharmacology (5 papers). Lynda Grinsted collaborates with scholars based in United Kingdom, United States and Canada. Lynda Grinsted's co-authors include Victoria Zazulina, Carlos H. Barrios, Alice T. Shaw, Paul D. Smith, Pasi A. Jänne, Fábio Franke, Lucio Crinò, G. Jeannin, Johan Vansteenkiste and José Rodrigues Pereira and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer.

In The Last Decade

Lynda Grinsted

18 papers receiving 1.4k citations

Hit Papers

Selumetinib plus docetaxel for KRAS-mutant advanced non-s... 2012 2026 2016 2021 2012 2016 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
    2012 512 citations Pasi A. Jänne, Alice T. Shaw et al. The Lancet Oncology profile →
  2. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
    2016 384 citations J.F.R. Robertson, Igor Bondarenko et al. The Lancet profile →

Peers

Lynda Grinsted
Jacqui Rowbottom United Kingdom
L Rhoda Molife United Kingdom
Gillian Ellison United Kingdom
Iván Díaz-Padilla United States
Richard Letrero United States
Patrick G. Pilié United States
Aglaya G. Iyevleva Russia
Angelica Fasolo Italy
Lydia Gaba Spain
Renata A. Coudry Brazil
Jacqui Rowbottom United Kingdom
Lynda Grinsted
Citations per year, relative to Lynda Grinsted Lynda Grinsted (= 1×) peers Jacqui Rowbottom

Countries citing papers authored by Lynda Grinsted

Since Specialization
Citations

This map shows the geographic impact of Lynda Grinsted's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lynda Grinsted with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lynda Grinsted more than expected).

Fields of papers citing papers by Lynda Grinsted

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lynda Grinsted. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lynda Grinsted. The network helps show where Lynda Grinsted may publish in the future.

Co-authorship network of co-authors of Lynda Grinsted

This figure shows the co-authorship network connecting the top 25 collaborators of Lynda Grinsted. A scholar is included among the top collaborators of Lynda Grinsted based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lynda Grinsted. Lynda Grinsted is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Rufibach, Kaspar, et al.. (2023). Quantification of follow‐up time in oncology clinical trials with a time‐to‐event endpoint: Asking the right questions. Pharmaceutical Statistics. 22(4). 671–691. 5 indexed citations
3.
4.
Fizazi, Karim, Daniel J. George, Maria De Santis, et al.. (2021). A phase III trial of capivasertib and abiraterone versus placebo and abiraterone in patients with de novo metastatic hormone-sensitive prostate cancer characterized by PTEN deficiency (CAPItello-281).. Journal of Clinical Oncology. 39(6_suppl). TPS178–TPS178. 24 indexed citations
5.
Hamilton, E.P., Gaia Schiavon, Lynda Grinsted, et al.. (2021). 338TiP CAPItello-292: A phase 1b/3 study of capivasertib, palbociclib and fulvestrant versus placebo, palbociclib and fulvestrant in HR+/HER2− advanced breast cancer. Annals of Oncology. 32. S514–S514. 5 indexed citations
6.
Hodgson, Darren, Brian Dougherty, Zhongwu Lai, et al.. (2018). Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. British Journal of Cancer. 119(11). 1401–1409. 167 indexed citations
7.
Ellis, Matthew J., Igor Bondarenko, Ekaterina Trishkina, et al.. (2016). FALCON: A phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer. Annals of Oncology. 27. vi554–vi554. 10 indexed citations
8.
Robertson, J.F.R., Igor Bondarenko, Ekaterina Trishkina, et al.. (2016). Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. The Lancet. 388(10063). 2997–3005. 384 indexed citations breakdown →
9.
10.
Hodgson, Darren, Brian Dougherty, Zefeng Lai, et al.. (2015). 435 Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. European Journal of Cancer. 51. S90–S90. 20 indexed citations
11.
Jänne, Pasi A., Alice T. Shaw, José Rodrigues Pereira, et al.. (2012). Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. The Lancet Oncology. 14(1). 38–47. 512 indexed citations breakdown →
12.
Naing, Aung, Carol Aghajanian, Éric Raymond, et al.. (2012). Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. British Journal of Cancer. 107(7). 1093–1099. 107 indexed citations
13.
Banerji, Udai, Emma Dean, Michael V. Gonzalez, et al.. (2012). First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors.. Journal of Clinical Oncology. 30(15_suppl). 3004–3004. 27 indexed citations
14.
15.
Jänne, Pasi A., Alice T. Shaw, José Rodrigues Pereira, et al.. (2012). Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 30(15_suppl). 7503–7503. 30 indexed citations
16.
Leijen, Suzanne, Patricia M.M.B. Soetekouw, T.R. Jeffry Evans, et al.. (2011). A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 68(6). 1619–1628. 37 indexed citations
17.
Banerji, Udai, Carol Aghajanian, Éric Raymond, et al.. (2011). First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor.. Journal of Clinical Oncology. 29(15_suppl). 3096–3096. 17 indexed citations
18.
Naing, Aung, Carol Aghajanian, Éric Raymond, et al.. (2011). Abstract A168: First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor.. Molecular Cancer Therapeutics. 10(11_Supplement). A168–A168. 7 indexed citations
19.
Grinsted, Lynda. (1990). [Allergic manifestations of nickel allergy in women with copper coils].. PubMed. 152(2). 111–111.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jacqui Rowbottom Breakdown of academic impact, for papers by L Rhoda Molife Breakdown of academic impact, for papers by Gillian Ellison Breakdown of academic impact, for papers by Iván Díaz-Padilla Breakdown of academic impact, for papers by Richard Letrero Breakdown of academic impact, for papers by Patrick G. Pilié Breakdown of academic impact, for papers by Aglaya G. Iyevleva Breakdown of academic impact, for papers by Angelica Fasolo Breakdown of academic impact, for papers by Lydia Gaba Breakdown of academic impact, for papers by Renata A. Coudry
Rankless by CCL
2026